IALILEPICCQERAA peptide sequence with a monodisperse polyethylene glycol tail
Sponsors
Realta Life Sciences Inc.
Conditions
Acute graft versus host disease (aGvHD)
Phase 2
Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients with Steroid -Refractory Acute Graft-versus-Host Disease
WithdrawnCTIS2024-510582-42-00
Target: 16Updated: 2024-07-08
Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients with Steroid -Refractory Acute Graft-versus-Host Disease
Active, not recruitingCTIS2024-510582-42-02
Start: 2025-08-14Target: 16Updated: 2025-07-24